ATE388944T1 - Indanessigsäure-derivate und ihre verwendung als pharmazeutische mittel, zwischenprodukten und verfahren zur herstellung - Google Patents
Indanessigsäure-derivate und ihre verwendung als pharmazeutische mittel, zwischenprodukten und verfahren zur herstellungInfo
- Publication number
- ATE388944T1 ATE388944T1 AT02750297T AT02750297T ATE388944T1 AT E388944 T1 ATE388944 T1 AT E388944T1 AT 02750297 T AT02750297 T AT 02750297T AT 02750297 T AT02750297 T AT 02750297T AT E388944 T1 ATE388944 T1 AT E388944T1
- Authority
- AT
- Austria
- Prior art keywords
- indanesic
- processes
- production
- acid derivatives
- pharmaceutical agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
- C07C51/44—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation by distillation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/303—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by hydrogenation of unsaturated carbon-to-carbon bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30850001P | 2001-07-27 | 2001-07-27 | |
US37304802P | 2002-04-16 | 2002-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE388944T1 true ATE388944T1 (de) | 2008-03-15 |
Family
ID=26976280
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02750297T ATE388944T1 (de) | 2001-07-27 | 2002-07-25 | Indanessigsäure-derivate und ihre verwendung als pharmazeutische mittel, zwischenprodukten und verfahren zur herstellung |
Country Status (33)
Country | Link |
---|---|
US (4) | US6828335B2 (de) |
EP (1) | EP1414809B1 (de) |
JP (1) | JP4510447B2 (de) |
KR (2) | KR100987267B1 (de) |
CN (1) | CN100528850C (de) |
AR (1) | AR036237A1 (de) |
AT (1) | ATE388944T1 (de) |
AU (2) | AU2002319693B2 (de) |
BR (1) | BR0211502A (de) |
CA (2) | CA2753329A1 (de) |
CO (1) | CO5560561A2 (de) |
CY (1) | CY1107370T1 (de) |
DE (1) | DE60225561T2 (de) |
DK (1) | DK1414809T3 (de) |
ES (1) | ES2302825T3 (de) |
HK (2) | HK1073653A1 (de) |
HR (1) | HRP20040076A2 (de) |
HU (1) | HUP0700105A2 (de) |
IL (3) | IL159960A0 (de) |
MA (1) | MA27063A1 (de) |
MX (1) | MXPA04000599A (de) |
MY (1) | MY139541A (de) |
NO (2) | NO20040356L (de) |
NZ (1) | NZ531351A (de) |
PE (1) | PE20030326A1 (de) |
PL (1) | PL374383A1 (de) |
PT (1) | PT1414809E (de) |
RU (1) | RU2314298C2 (de) |
SI (1) | SI1414809T1 (de) |
SV (1) | SV2003001186A (de) |
TW (2) | TWI345563B (de) |
UY (1) | UY27392A1 (de) |
WO (1) | WO2003011842A1 (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110065129A1 (en) * | 2001-07-27 | 2011-03-17 | Lowe Derek B | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
AR036237A1 (es) * | 2001-07-27 | 2004-08-25 | Bayer Corp | Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento |
US6833380B2 (en) | 2002-03-07 | 2004-12-21 | Warner-Lambert Company, Llc | Compounds that modulate PPAR activity and methods of preparation |
US6867224B2 (en) | 2002-03-07 | 2005-03-15 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods of preparation |
UA79755C2 (en) | 2002-04-16 | 2007-07-25 | Bayer Pharmaceuticals Corp | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
WO2004011446A1 (en) * | 2002-07-26 | 2004-02-05 | Bayer Pharmaceuticals Corporation | Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics |
AU2003299790A1 (en) * | 2002-12-20 | 2004-07-22 | Bayer Pharmaceuticals Corporation | Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
US7244763B2 (en) * | 2003-04-17 | 2007-07-17 | Warner Lambert Company Llc | Compounds that modulate PPAR activity and methods of preparation |
US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
WO2005110394A1 (ja) * | 2004-05-19 | 2005-11-24 | Ajinomoto Co., Inc. | 糖尿病治療薬 |
EP1781633A1 (de) * | 2004-08-20 | 2007-05-09 | Cadila Healthcare Limited | Neue verbindungen gegen diabetes |
JPWO2006057448A1 (ja) * | 2004-11-26 | 2008-06-05 | 武田薬品工業株式会社 | アリールアルカン酸誘導体 |
CA2647811A1 (en) | 2006-03-30 | 2007-10-11 | Asahi Kasei Pharma Corporation | Substituted bicyclic derivative and use thereof |
GB0712653D0 (en) | 2007-06-28 | 2007-08-08 | Syngenta Ltd | Novel herbicides |
GB0717082D0 (en) | 2007-09-03 | 2007-10-10 | Syngenta Ltd | Novel herbicides |
JP5198560B2 (ja) | 2008-04-28 | 2013-05-15 | 旭化成ファーマ株式会社 | フェニルプロピオン酸誘導体及びその用途 |
KR20110036709A (ko) * | 2008-06-23 | 2011-04-08 | 도아 에이요 가부시키가이샤 | 경피 흡수 촉진제 및 이를 사용한 경피 투여 제제 |
CA2740366A1 (en) * | 2008-10-21 | 2010-04-29 | Metabolex, Inc. | Aryl gpr120 receptor agonists and uses thereof |
TWI522109B (zh) * | 2009-01-26 | 2016-02-21 | 臺北醫學大學 | 蕨素化合物用於治療糖尿病及肥胖之用途 |
AR075401A1 (es) * | 2009-02-13 | 2011-03-30 | Sanofi Aventis | Indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento |
WO2010141690A2 (en) * | 2009-06-04 | 2010-12-09 | Dara Biosciences, Inc. | Indane analogs and use as pharmaceutical agents and process of making |
US20180200230A1 (en) * | 2009-06-04 | 2018-07-19 | Dara Biosciences, Inc. | Methods of treating neurodegenerative diseases using indane acetic acid derivatives which penetrate the blood brain barrier |
US20120141483A1 (en) * | 2009-06-04 | 2012-06-07 | Mary Katherine Delmedico | Methods of treating or preventing psoriasis, and/or alzheimer's disease using indane acetic acid derivatives |
EP2473515A4 (de) | 2009-09-04 | 2013-11-27 | Univ Toledo | Verfahren zur herstellung optisch reiner beta-laktone aus aldehyden und daraus hergestellte zusammensetzungen |
WO2012074980A2 (en) * | 2010-12-01 | 2012-06-07 | Dara Biosciences, Inc. | Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives |
AU2016235263A1 (en) * | 2015-03-26 | 2017-10-12 | T3D Therapeutics, Inc. | Methods of treating liver disease using indane acetic acid derivatives |
TWI712582B (zh) * | 2015-10-14 | 2020-12-11 | 法商領先藥物公司 | 用來製備(5s,10s)-10-苄基-16-甲基-11,14,18-三側氧基-15,17,19-三氧雜-2,7,8-三噻基-12-氮二十一烷基-5-銨基(e)-3-羧基丙烯酸鹽的工業方法 |
US20180153859A1 (en) * | 2016-12-02 | 2018-06-07 | T3D Therapeutics, Inc. | Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype |
US20180153860A1 (en) * | 2016-12-02 | 2018-06-07 | T3D Therapeutics, Inc. | Methods of dose administration for treating or preventing cognitive impairment using indane acetic acid derivatives |
US10919852B2 (en) | 2017-07-28 | 2021-02-16 | Chemocentryx, Inc. | Immunomodulator compounds |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3929923A (en) * | 1972-01-17 | 1975-12-30 | Sun Research Development | Process for preparation of isomers of 1-cyclohexyl-1,3,3-trimethylhydrindane |
US4754043A (en) * | 1985-10-03 | 1988-06-28 | American Home Products Corporation | Oxazole and thiazole naphthalenes as antiallergic agents |
FR2670491B1 (fr) * | 1990-12-14 | 1993-02-05 | Adir | Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
US5480896A (en) * | 1994-01-27 | 1996-01-02 | American Home Products Corporation | Aralkyl-1,2,4-oxadiazolidine-3,5-diones as antihyperglycemic agents |
US5939442A (en) * | 1995-06-07 | 1999-08-17 | The Salk Institute For Biological Studies | Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof |
JPH1087602A (ja) * | 1996-09-09 | 1998-04-07 | Zeria Pharmaceut Co Ltd | スルホンアミド誘導体、それを含有するトロンボキサン拮抗剤及び該化合物の製造中間体 |
AU8750298A (en) * | 1997-08-28 | 1999-03-22 | Ono Pharmaceutical Co. Ltd. | Peroxisome proliferator-activated receptor controllers |
JP2002543065A (ja) | 1999-04-28 | 2002-12-17 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ppap受容体リガンドとしてのトリアリール酸誘導体 |
HUP0201291A3 (en) | 1999-04-28 | 2002-11-28 | Sanofi Aventis Deutschland | Di-aryl acid derivatives as ppar receptor ligands and pharmaceutical compositions containing them |
ATE252091T1 (de) * | 1999-08-27 | 2003-11-15 | Lilly Co Eli | Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren |
EP1313715B1 (de) * | 2000-08-23 | 2007-08-01 | Eli Lilly And Company | Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten |
AR036237A1 (es) * | 2001-07-27 | 2004-08-25 | Bayer Corp | Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento |
-
2002
- 2002-07-19 AR ARP020102731A patent/AR036237A1/es unknown
- 2002-07-23 UY UY27392A patent/UY27392A1/es unknown
- 2002-07-25 CA CA2753329A patent/CA2753329A1/en not_active Abandoned
- 2002-07-25 BR BR0211502-6A patent/BR0211502A/pt not_active IP Right Cessation
- 2002-07-25 DE DE60225561T patent/DE60225561T2/de not_active Expired - Lifetime
- 2002-07-25 PT PT02750297T patent/PT1414809E/pt unknown
- 2002-07-25 HU HU0700105A patent/HUP0700105A2/hu unknown
- 2002-07-25 KR KR1020097023801A patent/KR100987267B1/ko active IP Right Grant
- 2002-07-25 AT AT02750297T patent/ATE388944T1/de active
- 2002-07-25 MX MXPA04000599A patent/MXPA04000599A/es active IP Right Grant
- 2002-07-25 SI SI200230691T patent/SI1414809T1/sl unknown
- 2002-07-25 NZ NZ531351A patent/NZ531351A/en not_active IP Right Cessation
- 2002-07-25 MY MYPI20022806A patent/MY139541A/en unknown
- 2002-07-25 AU AU2002319693A patent/AU2002319693B2/en not_active Expired
- 2002-07-25 PE PE2002000661A patent/PE20030326A1/es not_active Application Discontinuation
- 2002-07-25 JP JP2003517034A patent/JP4510447B2/ja not_active Expired - Fee Related
- 2002-07-25 DK DK02750297T patent/DK1414809T3/da active
- 2002-07-25 KR KR1020047001188A patent/KR100956898B1/ko active IP Right Grant
- 2002-07-25 WO PCT/US2002/023614 patent/WO2003011842A1/en active Application Filing
- 2002-07-25 CN CNB028186761A patent/CN100528850C/zh not_active Expired - Fee Related
- 2002-07-25 ES ES02750297T patent/ES2302825T3/es not_active Expired - Lifetime
- 2002-07-25 EP EP02750297A patent/EP1414809B1/de not_active Expired - Lifetime
- 2002-07-25 IL IL15996002A patent/IL159960A0/xx unknown
- 2002-07-25 RU RU2004105925/04A patent/RU2314298C2/ru active
- 2002-07-25 US US10/205,839 patent/US6828335B2/en not_active Expired - Lifetime
- 2002-07-25 PL PL02374383A patent/PL374383A1/xx unknown
- 2002-07-25 CA CA2455620A patent/CA2455620C/en not_active Expired - Lifetime
- 2002-07-26 SV SV2002001186A patent/SV2003001186A/es not_active Application Discontinuation
- 2002-07-26 TW TW099108854A patent/TWI345563B/zh not_active IP Right Cessation
- 2002-07-26 TW TW091116663A patent/TWI328008B/zh not_active IP Right Cessation
-
2004
- 2004-01-20 IL IL159960A patent/IL159960A/en unknown
- 2004-01-23 HR HR20040076A patent/HRP20040076A2/hr not_active Application Discontinuation
- 2004-01-26 NO NO20040356A patent/NO20040356L/no not_active Application Discontinuation
- 2004-02-23 CO CO04015672A patent/CO5560561A2/es not_active Application Discontinuation
- 2004-02-27 MA MA27553A patent/MA27063A1/fr unknown
- 2004-09-22 US US10/949,119 patent/US7112597B2/en not_active Expired - Lifetime
-
2005
- 2005-06-17 HK HK05105077.0A patent/HK1073653A1/xx not_active IP Right Cessation
-
2006
- 2006-05-05 US US11/429,136 patent/US7358386B2/en not_active Expired - Lifetime
-
2007
- 2007-04-25 HK HK07104418.9A patent/HK1098125A1/xx not_active IP Right Cessation
-
2008
- 2008-03-27 CY CY20081100353T patent/CY1107370T1/el unknown
- 2008-03-31 US US12/059,706 patent/US20090047687A1/en not_active Abandoned
- 2008-08-04 NO NO20083411A patent/NO20083411L/no not_active Application Discontinuation
- 2008-10-29 AU AU2008237581A patent/AU2008237581A1/en not_active Abandoned
-
2010
- 2010-10-24 IL IL208891A patent/IL208891A/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE388944T1 (de) | Indanessigsäure-derivate und ihre verwendung als pharmazeutische mittel, zwischenprodukten und verfahren zur herstellung | |
ATE344034T1 (de) | N-adamantylmethyl-derivate und zwischenprodukte als pharmazeutische zusammensetzungen und verfahren zu ihrer herstellung | |
ATE490256T1 (de) | Neue cyanopyrrolidide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
ATE438645T1 (de) | 7-phenylamino-4-chinolon-3-carbonsäure-derivate verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
ATE528288T1 (de) | Anthranilsäureamide, verfahren zu ihrer herstellung, ihre verwendung als antiarrhythmika sowie pharmazeutische zubereitungen davon | |
ATE332898T1 (de) | Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel | |
ATE265424T1 (de) | Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
ATE302754T1 (de) | Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
ATE496919T1 (de) | Dihydropteridinonderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel | |
DE60336264D1 (de) | Indanessigsäure-derivate und ihre verwendung als pharmazeutische mittel sowie zwischenprodukte und methoden zu ihrer herstellung | |
ATE393769T1 (de) | Stickstoff substituierte hexahydro-pyrazino 1,2-a pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
ATE353900T1 (de) | Xanthinderivate, deren herstellung und deren verwendung als arzneimittel | |
DE502005009723D1 (de) | Arylsubstituierte heterozyklen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
ATE396198T1 (de) | 17alpha-alkyl-17beta-oxy-estratriene und zwischenprodukte zu deren herstellung, verwendung der 17alpha-alkyl-17beta-oxy-estratriene zur herstellung von arzneimitteln sowie pharmazeutische präparate | |
ATE472548T1 (de) | Substituierte hexahydro-pyrazino(1,2-a)pyrimidin- 4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
ATE327981T1 (de) | Arylisoxazolin-derivative, verfahren zu ihrer herstellung und ihre verwendung als schädlingsbekämpfungsmittel | |
ATE323092T1 (de) | Pyridopyrimidinon-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
ATE245160T1 (de) | Derivate von erythromycin, ihr verfahren zur herstellung, und ihre verwendung als arzneimittel | |
ATE304534T1 (de) | Aminocarbonyl-substituierte benzimidazolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
ATE302765T1 (de) | 2-arylimino-2,3-dihydrothiazol derivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung | |
ATE411979T1 (de) | Derivate von c2-substituierten indan-1-ol- systemen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
DE60200041D1 (de) | Indenoindolon-Derivate, Verfahren zu ihrer Herstellung und die enthaltenden pharmazeutischen Zusammensetzungen | |
ATE344265T1 (de) | Derivate von benzothiazin und benzothiadiazin, verfahren zu ihrer herstellung und pharmazeutische zubereitungen diese enthaltend | |
ATE248171T1 (de) | Isoindoloindolon-derivate, verfahren zu ihrer herstellung und die enthaltende pharmazeutische zusammensetzungen | |
ATE323097T1 (de) | Neue 5-thio-ss-d-xylopyranosidderivate, verfahren zu deren herstellung, diese enthaltende pharmazeutische zusammensetzungen und deren therapeutische verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1414809 Country of ref document: EP |